Trials / Terminated
TerminatedNCT04860466
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL). The study will be conducted in 2 parts: Part A, monotherapy dose escalation and Part B, monotherapy dose expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-96673 | IV Infusion |
Timeline
- Start date
- 2022-01-20
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
- First posted
- 2021-04-27
- Last updated
- 2024-10-16
Locations
13 sites across 4 countries: United States, Canada, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04860466. Inclusion in this directory is not an endorsement.